Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant factor VIIa - rEVO Biologics/LFB

Drug Profile

Recombinant factor VIIa - rEVO Biologics/LFB


Latest Information Update: 12 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer HEMA Biologics; LFB Biotechnologies; rEVO Biologics
  • Class Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia A; Haemophilia B

Most Recent Events

  • 06 Aug 2017 LFB completes the phase III PERSEPT3 trial in Haemophilia A & B (In infants, In children, In adults, In adolescents, In the elderly) in Ukraine, USA, Mexico, Russia, South Africa and Spain (Parenteral) (NCT02548143)
  • 09 Jan 2017 Preregistration for Haemophilia A and Haemophilia B (In adolescents, In adults, In children, In infants) in USA (Parenteral)
  • 09 Jan 2017 Efficacy and adverse events data from the phase III PERSEPT 1 trial in Hemophilia A and B released by LFB Biotechnologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top